Cizzle Biotechnology plc (LON:CIZ) Executive Chairman Allan Syms joins DirectorsTalk to discuss the signing of an MOU with St George Street Capital. Allan explains what a companion diagnostic is, what St George Street Capital do, what the proposed commercial agreement will cover and what Cizzle Biotech is looking to achieve over the coming months.
Cizzle Biotechnology is a UK based developer of A blood test for the early detection of a majority of different forms of lung cancer.
Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer, has announced that it has signed an extension to its exclusive licensing and partnership agreement for the USA and Canada, executed on 21 October 2024, with Cizzle
Cizzle Biotechnology plc (LON:CIZ) Executive Chairman Dr Allan Syms caught up with DirectorsTalk for an exclusive interview to discuss the unique advantages of the CIZ1B biomarker, BIO’s partnership strategy, the Moffat Cancer Centre collaboration, strategy for
Cizzle Biotechnology plc (LON:CIZ) Executive Chairman Dr Allan Syms joins DirectorsTalk Interviews to discuss an exclusive licensing and partnership agreement for its proprietary CIZ1B biomarker. In this interview, Cizzle Biotechnology’s Executive Chairman, Dr Allan Syms, provides valuable
Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer, has announced that it has today signed an exclusive licensing and partnership agreement for its proprietary CIZ1B biomarker test to help detect early-stage lung cancer, throughout the USA and
Cizzle Biotechnology plc (LON:CIZ) Executive Chairman Dr Allan Syms joins DirectorsTalk Interviews to discuss a collaboration with Moffitt Cancer Center the number one cancer hospital in Florida and the Southeast USA. In this insightful interview, Dr Allan
Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics company focused on developing a cost-effective biomarker test to help detect early-stage lung cancer, has announced that it has been selected by the Moffitt Cancer Center, the number
Cizzle Biotechnology Holdings plc (LON:CIZ), the UK-based diagnostics company focused on developing a cost effective biomarker test to help detect early-stage lung cancer, has announced a strategic agreement with BBI Solutions, the world’s largest independent producer of
Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer, has announced the publication of the Company’s Annual Report and Financial Statements for the year ended 31 December 2023: Cizzle Biotechnoloy is developing a blood test
Cizzle Biotechnology plc’s Executive Chairman discusses new Licensing and Partnership MoU for North America, focusing on revenue streams and market expansion.
Cizzle Biotechnology plc (LON:CIZ) Executive Chairman Dr Allan Syms joins DirectorsTalk Interviews to discuss a strategic and exclusive licensing agreement to develop and offer its proprietary test throughout the USA and Canada. Dr. Alan Syms, discusses the
Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer, has announced that it has signed a non-binding Memorandum of Understanding for a strategic and exclusive licensing agreement to develop and offer its proprietary test for the CIZ1B
Cizzle Biotechnology Holdings PLC (LON:CIZ), the UK based diagnostics developer, has announced that it has undertaken a conditional placing of 31,050,000 new ordinary shares of 0.01p each in the Company at a price of 2 pence per share
Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer, has announced a further update regarding the Company’s put option to sell its 5% economic interest and royalty sharing agreement in the AZD 1656 asset to treat
Cizzle Biotechnology plc (LON:CIZ) Executive Chairman Dr Allan Syms joins DirectorsTalk Interviews to the completion of its Evaluation Programme with Bio-Techne for Cizzle’s CIZ1B cancer biomarker. Allan reminds us of what the CIZ1B biomarker is, how this
Bio-Techne Corporation (NASDAQ: TECH) and Cizzle Biotechnology Holdings plc (LON:CIZ), the UK-based diagnostics developer, have announced recent progress evaluating specific monoclonal antibodies for Cizzle’s CIZ1B cancer biomarker. Cizzle has successfully completed an evaluation programme aimed at assessing the feasibility of
Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer, has announced a further update regarding the Company’s put option to sell its 5% economic interest and royalty sharing agreement in the AZD 1656 asset to treat
Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer, has announced an expansion of its current research programme with the University of York to develop its CIZ1B biomarker technology for early stage cancer diagnosis, and other potential
Cizzle Biotechnology (LON:CIZ), the UK-based diagnostics developer, has announced that it has conditionally raised gross proceeds of £350,000 (before expenses of £17,500) by way of the issue of 16,666,667 new Ordinary Shares at 2.1p per share with
© 2025 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.